$10.37 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



IsoPlexis Corporation is a life sciences company. It is engaged in building solutions to develop curative medicines and personalized therapeutics. The Company's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The Company's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments is designed to be automated benchtop proteomic hubs. Its IsoCode chips uses it technology proteomic barcoding to capture single cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. IsoSpeak software provides automated data analysis and accelerated insights. Its subsidiary includes IsoPlexis UK Limited.

Stock Analysis

last close $10.37
1-mo return -16.6%
3-mo return -
avg daily vol. 142.18T
52-week high 16.95
52-week low 8.65
market cap. $545M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. -
inst own. 62.1%

Subscribe now for daily local and international financial news